Skip to main content
Have a personal or library account? Click to login
The Various Shapes of Innovation Cover

The Various Shapes of Innovation

Forum of Clinical Oncology
Volume 6 (2015): Issue 4 (December 2015)
By:  and    
Open Access
|Mar 2016
References

References

  1. [1] Vincent K. Omachonu NGE. Innovation in Healthcare Delivery Systems: A Conceptual Framework. The Public Sector Innovation Journal. 2010; 15(1):1-20.
    Search in Google Scholar
  2. [2] Lansisalmi H, M. Kivimaki, P. Aalto, and R. Ruoranen. Innovation in Healthcare: A Systematic Review of Recent Research. Nursing Science Quarterly. 2006; 19:66-72.
    Open DOISearch in Google Scholar
  3. [3] Hult KJ. Incremental Innovation and Pharmaceutical Productivity. 2014.
    Search in Google Scholar
  4. [4] Varkey P, Horne A, Bennet KE. Innovation in health care: a primer. American journal of medical quality : the official journal of the American College of Medical Quality. 2008; 23(5):382-8.
    Open DOISearch in Google Scholar
  5. [5] Ruud E.H.M S, Wouter P.C. Boon. The role of users in innovation in the pharmaceutical industry. Drug Discovery Today. 2008; 13(7/8):353-9.
    Open DOISearch in Google Scholar
  6. [6] Kaitin KI. The Landscape for Pharmaceutical Innovation: Drivers of Cost-Effective Clinical Research. Pharmaceutical outsourcing. 2010; 2010.
    Search in Google Scholar
  7. [7] Schulthess D, Chlebus M, Bergstrm R, et al. Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law. Chinese clinical oncology. 2014; 3(2):21.
    Search in Google Scholar
  8. [8] Collyar D. CR. A rennaissance in biomedical innovation: global villages raise effective therapies. Future Medicinal Chemistry. 2015; 7:971-9+74.
    Open DOISearch in Google Scholar
  9. [9] Montgomery JLaCM. The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development. Science, Technology, & Human Values. 20104; 40(1):3-29.
    Open DOISearch in Google Scholar
  10. [10] Reddy R. The Future of Pharma: A U.S. Sector Review. Cognizant Reports. 2011.
    Search in Google Scholar
  11. [11] M G. The Innovative Medicines Initiative: A European Response to the Innovation Challenge. Clinical Pharmacology & Therapeutics. 2012; 91(3):418-25.
    Open DOISearch in Google Scholar
  12. [12] The right prevention and treeatment for the right patient at the right time: Strategic Research Agenda for Innovative Medicines Initiative 2. EFPIA. Spring 2014.
    Search in Google Scholar
  13. [13] Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, Preventive and Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position paper. The EPMA journal. 2014; 5(1):6.
    Open DOISearch in Google Scholar
  14. [14] Piccart-Gebhart MJ PM, Leyland-Jones Bet al. The Case for Personalized Medicine. Personalised Medicine Coalition 2009.
    Search in Google Scholar
  15. [15] Y. Touchefeu KJH, J. P. Galmiche & G. Vassaux. Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology. Alimentary Pharmacology and Therapeutics. 2010; 32:953-68.
    Open DOISearch in Google Scholar
  16. [16] Misra S. Human gene therapy: a brief overview of the genetic revolution. The Journal of the Association of Physicians of India. 2013; 61(2):127-33.
    Search in Google Scholar
  17. [17] Patil P.M. CPD, Megha Sahu, Duragkar N.J. REVIEW ARTICLE ON GENE THERAPY. International Journal of Genetics. 2012; 4(1):74-9.
    Open DOISearch in Google Scholar
  18. [18] Stevens W, Philipson TJ, Khan ZM, et al. Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007. Health affairs. 2015; 34(4):562-70.
    Open DOISearch in Google Scholar
  19. [19] Lichtenberg FR. Pharmaceutical Innovation and Longevity Growth in 30 developing high-income countries, 2000-2009. NBER Working Paper Series. 2013.
    Open DOISearch in Google Scholar
  20. [20] America PRaMo. 2012 Pharmaceutical Industry Profile. 2012.
    Search in Google Scholar
  21. [21] Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006; 17(2):239-45.
    Open DOISearch in Google Scholar
  22. [22] Edward L. Korn, Boris Freidlin, Jeffrey S. Abrams, and Susan Halabi. Design Issues in Randomized Phase II/III Trials. Journal of Clinical Oncology. Vol 30, No 6, Feb 20 2012.
    Open DOISearch in Google Scholar
  23. [23] Peter K. Kimani, Susan Toddb and Nigel Stallarda. Conditionally unbiased estimation inphase II/III clinical trials with early stopping for futility. Statistics in Medicine. 2013, 32 2893–2910
    Open DOISearch in Google Scholar
  24. [24] Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute. 2010; 102(3):152–160. [PubMed: 20075367]
    Open DOISearch in Google Scholar
  25. [25] Ryan D. Gentzler, Sarah E. Yentz, Melissa L. Johnson, Alfred W. Rademaker, and Jyoti D. Patel. The Changing Landscape of Phase II/III Metastatic NSCLC Clinical Trials and the Importance of Biomarker Selection Criteria. Cancer 2014;120:3853-8.
    Open DOISearch in Google Scholar
  26. [26] Henrik Zetterberg*, Niklas Mattsson, Kaj Blennow and Bob Olsson. Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer’s Research & Therapy 2010, 2:32.
    Open DOISearch in Google Scholar
  27. [27] Shein-Chung Chow and Ralph Corey. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet Journal of Rare Diseases 2011, 6:79.
    Open DOISearch in Google Scholar
  28. [28] Daniel Schneider, Giampaolo Bianchini, Denis Horgan, Stefan Michiels, Wim Witjes, Robert Hills, Juliette Plun-Favreau, Angela Brand, Mark Lawler. Public Health Genomics 2015;18:349–358.
    Open DOISearch in Google Scholar
  29. [29] Ada Hang-Heng Wong, Chu-Xia Deng. Precision Medicine for Personalized Cancer Therapy.2015, Vol. 11.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/fco-2015-0019 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 12 - 22
Submitted on: Nov 19, 2015
Accepted on: Jan 7, 2016
Published on: Mar 31, 2016
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Keywords:
Innovation,
Personalised medicine,
IMI,
MAPPs,
Horizon 2020
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2016 I. Roubou, D.K. Alexopoulou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 6 (2015): Issue 4 (December 2015)
Previous article
Next article